Since 2020, approximately 1,000 new cases of HIV-1 infection have been reported each year in Korea. Among these cases, the proportion of foreign nationals accounted for 26.8% of new diagnoses in 2024 [1]. The introduction of antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal disease into a manageable chronic condition.
It is recommended that ART regimens contain at least three active substances from two or more classes [2]. Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide, BIC/FTC/TAF) was approved in Korea in 2019 for the treatment of HIV-1 infection. BIC/FTC/TAF is a combination of BIC, an HIV-1 integrase strand transfer inhibitor, and two HIV-1 nucleoside analog reverse transcriptase inhibitors FTC and TAF [34].
A 6-year prospective, multicenter, observational post-marketing surveillance (PMS) study was started in July 2019 to assess the safety and effectiveness of BIC/FTC/TAF during routine use under real-world conditions in Korea. Patients were enrolled at 45 sites. This study included adults with HIV-1 infection eligible for BIC/FTC/TAF treatment, as per approved Korean prescribing information.
Patients were managed according to local treatment guidelines and/or routine clinical practice, with no requirement for additional diagnostic tests or monitoring procedures. Safety was assessed up to 52 weeks post BIC/FTC/TAF initiation. Data were obtained from the medical records of eligible patients.
Data was collected on demographics, clinical characteristics, HIV-1 infection history, medical history, BIC/FTC/TAF treatment status (whether they completed the 48-week observation period), other medication information (prior medication, concomitant medication, prior ART, and post-BIC/FTC/TAF ART), subgroup characteristics, safety assessments, and effectiveness assessments (CD4+ T-cell count, HIV-1 RNA viral load, and investigator assessment of effectiveness). Treatment observation was considered complete after 48 weeks on BIC/FTC/TAF, and effectiveness outcomes were assessed using data collected within 36 to 64 weeks of therapy initiation.
Adverse events (AEs) were collected from the start of treatment to 30 days after completion or discontinuation of BIC/FTC/TAF. AEs and adverse drug reactions (ADRs) were classified by system organ class and preferred term (PT; English/Korean) under the classification standard of the Medical Dictionary for Regulatory Activities (MedDRA) Version 24.0 (until 31 October 2021) and Version 25.1 (from 1 November 2021 onward). ADRs were defined as any unintended or harmful response considered causally related to BIC/FTC/TAF.
The causal relationship between BIC/FTC/TAF and AEs was assessed by the investigator using modified WHO-UMC categories [5]. The causal relationship of AEs to BIC/FTC/TAF treatment was characterized as certain, probable, possible, unlikely, conditional/unclassified, or un-assessable/unclassifiable. AEs were considered causally related BIC/FTC/TAF if it was deemed by the prescribing physician to be certain, probable, possible, conditional/unclassified, or un-assessable/unclassifiable.
Serious adverse events (SAEs) were classified by the prescribing physician as events resulting in death, life-threatening illness, prolonged hospitalization, persistent or significant disability, congenital anomalies, or other medically important conditions. Special situation reports (SSRs) and unexpected AE not listed in the reference safety information in Korea were also collected. Additionally, other safety events not categorized above such as hepatic or renal impairment were documented and assessed at baseline by the prescribing physicians.
HIV-1 RNA and CD4+ T-cell count was assessed at baseline and again at 48-week after treatment initiation. The proportion of patients achieving virologic success (defined as HIV-1 RNA <50 copies/mL at the last visit), and changes in CD4+ T-cell count from baseline were tabulated and compared across patient subgroups.
At the conclusion of the treatment observation period, prescribing physicians were also asked to assess the effectiveness of BIC/FTC/TAF by selecting one of three options: improved, unchanged, or worsened. This assessment was based on measurements of plasma HIV-1 RNA and CD4+ T-cell counts.
The cumulative frequencies of AEs, serious AEs, ADRs, serious ADRs, and SSRs were compared between subgroups by patient characteristics, using Chi-square or Fisher exact tests (α=0.05). Effectiveness was evaluated by analyzing the proportion of patients with virologic success defined as HIV-1 RNA <50 copies/mL at last visit and change in CD4+ T-cell count, across subgroups by patient characteristics (Chi-square or Fisher exact tests; α=0.05). Investigators also assessed at the last visit whether the patient was ‘improved’, ‘unchanged’, or ‘worsened’ based on following instructions; (1) proportion of patients achieving virologic success (HIV-1 RNA<50 copies/mL at last visit), (2) change in CD4+ T-cell count from baseline to last visit, and or (3) physician’s global assessment of treatment effectiveness(improved, unchanged, or worsened) recorded in the case record form.
All statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC, USA).
During the surveillance period from 18 January 2022 to 17 January 2023, 34 study sites collected case report forms from 1,163 patients, of whom 1,157 were included in the safety analysis set (Supplementary Fig. 1).
Demographics and clinical characteristics of the safety analysis set are summarized. At the start of treatment, most patients were male (93.3%) and outpatients (99.0%). Mean age (±standard deviation, SD) was 43.3 (±13.7 years), ranging from 20 to 85 years.
Most patients (89.3%) were ART experienced (TE). The most common reason for switching to BIC/FTC/TAF among TE patients was availability of a new medication (98.5%). At the time of enrollment, 89 patients (7.7%) in the safety analysis set were aged ≥65 years, 60 patients (5.2%) had hepatic impairment, and 17 patients (1.5%) had renal impairment.
One pregnancy (0.1%) was reported during the surveillance period (Table 1). A total of 1,080 patients (93.3%) completed the full 48-week of BIC/FTC/TAF treatment, while 77 patients (6.7%) discontinued treatment. The reasons for treatment discontinuation were ‘lost to follow-up’ in 44 patients (3.8%), ‘adverse event’ in 21 patients (1.8%), and ‘other’ in 12 patients (1.0%).
The AEs that led to BIC/FTC/TAF discontinuation and occurred more than once were ‘alanine aminotransferase (ALT) increased’ (6 events), ‘aspartate aminotransferase (AST) increased’ (5 events), ‘pruritus’ (3 events), and insomnia (2 events). No patient reported BIC/FTC/TAF discontinuation due to lack of efficacy (Supplementary Table 1).
A total of 755 AEs were reported in 425 patients (36.7%). The most frequently reported AEs by PT were ‘weight increased’ (n=21; 1.8%), ‘nasopharyngitis’ (n=19; 1.6%), and ‘headache’, ‘ALT increased’, ‘AST increased’, and ‘insomnia’ in 18 patients each (1.6%). Of these 755 AEs, 88 were considered ADRs reported in 63 patients (5.5%).
The most frequently reported ADRs were ‘insomnia’ (n=9, 0.8%), ‘ALT increased’ (n=7, 0.6%), and ‘AST increased’ (n=6, 0.5%; Table 2). Of all AEs, 46 were considered SAEs reported in 41 patients (3.5%). None of the reported SAEs was considered a serious ADR, i.e. causally related (Supplementary Table 2).
There were no ADRs with a frequency of ≥1%. The most frequently reported ADR was insomnia which was reported in 9 patients. The majority of AEs (83.6%), ADRs (76.1%), and SAEs (95.6%) were classified as `recovered/resolved’ or ‘recovering/resolving’.
The one reported pregnancy resulted in a healthy live birth. No deaths were reported during this surveillance period.
The high virological success rate reported in this study underscores the effectiveness of BIC/FTC/TAF and value offered to patients in routine clinical practice. Among 973 patients in the effectiveness analysis set, 872 (89.6%) were TE and 101 (10.4%) were ART naïve (TN) at the start of treatment with BIC/FTC/TAF. The success rate for virological response (plasma HIV-1 RNA <50 copies/mL) at 48-week after initiation of BIC/FTC/TAF treatment was 96.7% (n=941) (Supplementary Table 3).
An increase in median [interquartile range] CD4+ T-cell count from baseline to last visit was observed in both TE (28.0 [-73.0, 136.0]) and TN (221.0 [138.0, 403.0]) patients (all P<0.0001; Table 3). Overall, 919 patients (94.3%) in the effectiveness analysis set were assessed by investigators as ‘improved’ and 56 patients (5.7%) were assessed as ‘unchanged’ at 48-week after initiation of BIC/FTC/TAF. No patient was assessed as ‘worsened’.
Analysis of data from the fourth year of this 6-year PMS study is in line with the observational study results published on the safety and effectiveness of BIC/FTC/TAF in patients with HIV-1 infection treated in routine clinical practice [6789].
Although several reported ADRs (e.g., weight increase, headache, diarrhea) in this study are labeled in the Korean BIC/FTC/TAF prescribing information, some reported ADRs (insomnia, increased ALT, and AST) are not, meaning these were unexpected events. Elevation of liver enzymes is not uncommon in HIV-infected patients taking antiretroviral medications, although rates with contemporary regimens are lower than with earlier regimens [10]. General steps for mitigating liver enzyme elevation include the elimination of hepatotoxins, screening for and treating viral hepatitis, and stopping or switching the suspected offending drug(s) [10].
In this study, BIC/FTC/TAF was discontinued in nearly all patients who experienced increased ALT (6 out of 7 patients) and in most patients who experienced increased AST (5 out of 6 patients).
While this study represents one of the largest real-world BIC/FTC/TAF datasets in Asia and provides robust insights into treatment outcomes in real-world clinical settings, it has limitations which are typical for observational studies. These include selection bias (non-random selection of patients) and sporadic lack of data collection, due to the nature of the study and physician discretion. When missing data is related to outcome measures, it could lead to over- or underestimation of study results.
In conclusion, data analysis from the fourth year of this ongoing PMS study supports the safety and effectiveness of BIC/FTC/TAF in routine clinical practice in Korea. Less than 2% of patients reported AEs or ADRs that led to discontinuation of BIC/FTC/TAF. No new and significant safety issues emerged.
The benefit-risk balance of BIC/FTC/TAF remains positive and no update to the Korean prescribing information is warranted at this time.